SpringerLink
Log in

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease. Aim of the present study was to analyze oligoprogressive prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) during systemic treatment to identify predictive factors and improve patients’ selection. We included PC patients treated with SBRT on a maximum of 3 sites of oligoprogression during systemic therapy. Endpoints were freedom from polymetastatic progression (FPP), local control (LC), distant progression free survival (DPFS), overall survival (OS), and next systemic therapy free survival (NEST-FS). Fifty-three patients were treated on 85 oligoprogressive metastases. Lymph nodes were the most common sites (56.47%), followed by bone (39.29%). Median follow-up was 24.9 months. Rates of FPP at 1- and 2-year were 80.1% and 68.9%, respectively. Median time to polymetastatic progression was 33.7 months. Disease free interval (p = 0.004), site of metastases (p = 0.011), and type of systemic therapy (p = 0.003) were significant for FPP. Switch or intensification of systemic therapy after SBRT was observed in 29 (54.72%) patients with a median NEST-FS of 15.2 months. LC at 1- and 2-year was 94.0% and 92.0%, with PSA doubling time resulted to be significantly associated (p = 0.047). Median DPFS was 8.93 months and median OS was 50.6 months. In conclusion, we confirmed the efficacy of SBRT for oligoprogression from PC, with the potential to prolong the on-going systemic therapy and interrupt the metastatic cascade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Abbreviations

PC:

Prostate cancer

ADT:

Androgen deprivation therapy

ARTA:

Androgen recepto targeted agents

MDT:

Metastases-directed therapies

SBRT:

Stereotactic body radiation therapy

LC:

Local control

PET:

Positron emitting tomography

PSMA:

Prostate-specific membrane antigen

CTV:

Clinical target volume

GTV:

Gross target volume

PTV:

Planning target volume

FPP:

Freedom from polymetastatic progression

DPFS:

Distant progression free survival

OS:

Overall survival

NEST-FS:

Next systemic therapy free survival

Gy:

Gray

BED:

Biological effective dose

References

  1. Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/jco.1995.13.1.8

    Article  CAS  PubMed  Google Scholar 

  2. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, DeSouza NM et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18-28. https://doi.org/10.1016/S1470-2045(19)30718-1

    Article  PubMed  Google Scholar 

  3. McDonald E, Cheng S, Arciero VS, Saluja R, Zukotynski KA, Cheung P et al (2017) Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy. J Clin Oncol 35:e587–e587. https://doi.org/10.1200/jco.2017.35.6_suppl.e587

    Article  Google Scholar 

  4. Hong MKH, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S et al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605. https://doi.org/10.1038/ncomms7605

    Article  CAS  PubMed  Google Scholar 

  5. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A et al (2020) Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol 77:508–547. https://doi.org/10.1016/j.eururo.2020.01.012

    Article  CAS  PubMed  Google Scholar 

  6. D’Angelillo RM, Francolini G, Ingrosso G, Ravo V, Triggiani L, Magli A et al (2019) Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol 138:24–28. https://doi.org/10.1016/j.critrevonc.2019.03.014

    Article  PubMed  Google Scholar 

  7. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Jack Lee J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558–1565. https://doi.org/10.1200/JCO.19.00201

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5

    Article  PubMed  Google Scholar 

  9. Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F et al (2019) Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. https://doi.org/10.1016/j.radonc.2018.10.024

    Article  PubMed  Google Scholar 

  10. Franzese C, Paolo AZ, Di Brina L, D’agostino G, Navarria P et al (2018) The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. Cancer Med 7:4379–4386. https://doi.org/10.1002/cam4.1707

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A et al (2019) Oligometastatic prostate cancer: the game is afoot. Cancer Treat Rev 73:84–90. https://doi.org/10.1016/j.ctrv.2019.01.005

    Article  PubMed  Google Scholar 

  12. Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K et al (2021) Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol 4:305–309. https://doi.org/10.1016/j.euo.2019.08.012

    Article  PubMed  Google Scholar 

  13. Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C et al (2021) Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol 4:447–455. https://doi.org/10.1016/j.euo.2020.05.004

    Article  PubMed  Google Scholar 

  14. Yoshida S, Takahara T, Arita Y, Ishii C, Uchida Y, Nakagawa K et al (2019) Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor. Int J Radiat Oncol 105:376–381. https://doi.org/10.1016/j.ijrobp.2019.06.011

    Article  Google Scholar 

  15. Triggiani L, Mazzola R, Magrini SMSM, Ingrosso G, Borghetti P, Trippa F et al (2019) Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol 37:2631–2637. https://doi.org/10.1007/s00345-019-02717-7

    Article  CAS  PubMed  Google Scholar 

  16. Valeriani M, Detti B, Fodor A, Caini S, Borghesi S, Trippa F et al (2022) Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis. Radiol Med 127:108–116. https://doi.org/10.1007/s11547-021-01424-x

    Article  PubMed  Google Scholar 

  17. Eisenhauer EA, Verweij J (2009) 11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1. Eur J Cancer Suppl 7:5. https://doi.org/10.1016/S1359-6349(09)70018-7

    Article  Google Scholar 

  18. Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650–659. https://doi.org/10.1001/jamaoncol.2020.0147

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke FDMG (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018(36):446–453. https://doi.org/10.1200/JCO.2017.75.4853

    Article  Google Scholar 

  20. Decaestecker K, De Meerleer G, Lambert B (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:1–10

    Article  Google Scholar 

  21. Francolini G, Loi M, Detti B, Desideri I, Mangoni M, Simontacchi G et al (2021) Integrating stereotactic body radiation therapy (SBRT) and systemic treatments in oligoprogressive prostate cancer: new evidence from the literature. Clin Exp Metastasis 38:227–230. https://doi.org/10.1007/s10585-021-10072-4

    Article  PubMed  Google Scholar 

  22. Ingrosso G, Detti B, Fodor A, Caini S, Borghesi S, Triggiani L et al (2021) Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol 23:1577–1584. https://doi.org/10.1007/s12094-021-02553-5

    Article  CAS  PubMed  Google Scholar 

  23. Onal C, Kose F, Ozyigit G, Aksoy S, Oymak E, Muallaoglu S et al (2021) Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate 81:543–552. https://doi.org/10.1002/pros.24132

    Article  CAS  PubMed  Google Scholar 

  24. Detti B, D’Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L et al (2017) Combining abiraterone and radiotherapy in prostate cancer patients who progressed during abiraterone therapy. Anticancer Res 37:3717–3722. https://doi.org/10.21873/anticanres.11744

    Article  CAS  PubMed  Google Scholar 

  25. Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L et al (2021) Metastasis-directed therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer 19:230–236. https://doi.org/10.1016/j.clgc.2020.08.002

    Article  PubMed  Google Scholar 

  26. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038. https://doi.org/10.1056/NEJMoa1315815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C et al (2019) Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 10:4213–4223. https://doi.org/10.18632/oncotarget.3925

    Article  PubMed  Google Scholar 

  28. Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J et al (2017) Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer. Eur Urol 71:874–882. https://doi.org/10.1016/j.eururo.2016.11.024

    Article  CAS  PubMed  Google Scholar 

  29. Joncas F, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F et al (2019) Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. Prostate 79:1767–1776. https://doi.org/10.1002/pros.23901

    Article  CAS  PubMed  Google Scholar 

  30. Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V et al (2021) Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). Clin Exp Metastasis 38:451–458. https://doi.org/10.1007/s10585-021-10118-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Francolini G, Garlatti P, Loi M, Detti B, Aquilano M, Allegra A et al (2021) ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensiv. J Clin Oncol 39:118–118. https://doi.org/10.1200/JCO.2021.39.6_suppl.118

    Article  Google Scholar 

Download references

Funding

No fundings were used for the present study.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, Milan, Italy

    Ciro Franzese, Marco Antonio Marzo, Beatrice Marini, Paolo Andrea Zucali & Marta Scorsetti

  2. Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy

    Ciro Franzese, Marco Antonio Marzo, Marco Badalamenti, Davide Baldaccini, Giuseppe D’Agostino, Beatrice Marini & Marta Scorsetti

  3. Department of Oncology, IRCCS Humanitas Research Hospital, 20089, Rozzano, Milan, Italy

    Matteo Perrino, Fabio De Vincenzo & Paolo Andrea Zucali

  4. Humanitas Research Hospital IRCCS, Humanitas University, Via Manzoni 56, Rozzano, Milan, Italy

    Ciro Franzese

Authors
  1. Ciro Franzese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matteo Perrino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Antonio Marzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Badalamenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Davide Baldaccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppe D’Agostino
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Beatrice Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fabio De Vincenzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paolo Andrea Zucali
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marta Scorsetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ciro Franzese.

Ethics declarations

Conflict of interest

All the authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Franzese, C., Perrino, M., Marzo, M.A. et al. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection. Clin Exp Metastasis 39, 449–457 (2022). https://doi.org/10.1007/s10585-022-10158-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-022-10158-7

Keywords

Search

Navigation